Long-term outcomes of the phase III study confirm that only the addition of carboplatin to paclitaxel impacts on pathological complete response and event-free survival
Reduced access to insurance, bank loans and mortgages makes financial constraints continue long after cancer has been treated
OnCOVID study reveals that respiratory symptoms, fatigue and cognitive/psychological dysfunction persist after acute Sars-CoV-2 infection, with an impact on survival and oncological outcomes after recovery
International oncology experts reunited as one oncology community to share the latest advances in the field at the ESMO annual meeting starting next week
With the “departure” of the virtual ESMO train in August, the ESMO Young Oncologists Committee (YOC) and the ESMO Climate Change Task Force are creating new opportunities for networking and sharing knowledge, while raising awareness on how climate change hits on cancer care
The scope of the oncology care across resource-diverse settings has been long debated.
Metastases are the main cause of cancer-related deaths. Preventing hibernating cancer cells from awakening therefore represents an urgent, unmet medical need.
Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women
Following more than two decades of extraordinary developments and advancements in cancer research – from molecular mechanisms to clinical care to new enabling technologies, we are better equipped than ever before to deliver a much more personalised, targeted form of cancer treatment and care.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.